Opus Genetics posts Q3 2025 results update

Opus Genetics, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025, and has shared these details through a press release.

Rhea-AI Filing Summary

Opus Genetics, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025, and has shared these details through a press release.

The company furnished this press release as Exhibit 99.1 to a current report, allowing investors to review the full quarterly results and commentary there. The information in this report and the exhibit is treated as furnished rather than filed under the securities laws, which affects how it is incorporated into other regulatory filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Opus Genetics (IRD) disclose in this 8-K filing?

Opus Genetics, Inc. furnished a current report noting that it issued a press release announcing its financial results for the third quarter ended September 30, 2025, which is attached as Exhibit 99.1.

Which period do the Opus Genetics (IRD) results in this update cover?

The results discussed in the press release furnished by Opus Genetics, Inc. cover the third quarter ended September 30, 2025.

Where can investors find the full Q3 2025 results for Opus Genetics (IRD)?

Investors can review the full third quarter 2025 financial results and related commentary in the press release attached as Exhibit 99.1 to this current report.

Is the Opus Genetics (IRD) Q3 2025 press release considered filed with the SEC?

The company states that the information in this report and Exhibit 99.1 is furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, or incorporated by reference into other filings unless specifically referenced.

On which exchange does Opus Genetics (IRD) trade and what is the listed security?

Opus Genetics, Inc. lists its common stock, $0.0001 par value per share, on The Nasdaq Stock Market LLC under the trading symbol IRD.

What exhibits are included with this Opus Genetics (IRD) current report?

The report includes Exhibit 99.1, a press release dated November 12, 2025, and Exhibit 104.1, the cover page interactive data file embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 07:07 AM Learn about SEC filing dates

false000122862700012286272025-11-122025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Opus Genetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-34079	11-3516358
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

8 Davis Drive Durham, NC		27713
(Address of principal executive offices)		(Zip Code)

(984) 884-6030

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	IRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated November 12, 2025.
104.1	Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2025	OPUS GENETICS, INC.
	By:	/s/ Dr. George Magrath
	Name:	Dr. George Magrath
	Title:	Chief Executive Officer